InterCure Statistics
Total Valuation
InterCure has a market cap or net worth of $63.67 million. The enterprise value is $108.60 million.
| Market Cap | 63.67M |
| Enterprise Value | 108.60M |
Important Dates
The next estimated earnings date is Wednesday, October 7, 2026, before market open.
| Earnings Date | Oct 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InterCure has 10.94 million shares outstanding. The number of shares has increased by 17.17% in one year.
| Current Share Class | 11.85M |
| Shares Outstanding | 10.94M |
| Shares Change (YoY) | +17.17% |
| Shares Change (QoQ) | -10.76% |
| Owned by Insiders (%) | 23.14% |
| Owned by Institutions (%) | 2.97% |
| Float | 8.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | 14.55 |
| P/OCF Ratio | 11.48 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 24.81 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.48 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | 13.11 |
| Interest Coverage | -3.42 |
Financial Efficiency
Return on equity (ROE) is -9.27% and return on invested capital (ROIC) is -12.62%.
| Return on Equity (ROE) | -9.27% |
| Return on Assets (ROA) | -5.78% |
| Return on Invested Capital (ROIC) | -12.62% |
| Return on Capital Employed (ROCE) | -14.12% |
| Weighted Average Cost of Capital (WACC) | 7.98% |
| Revenue Per Employee | $297,387 |
| Profits Per Employee | -$39,303 |
| Employee Count | 285 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.01 |
Taxes
| Income Tax | -2.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.59% in the last 52 weeks. The beta is 0.60, so InterCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -30.59% |
| 50-Day Moving Average | 4.99 |
| 200-Day Moving Average | 4.77 |
| Relative Strength Index (RSI) | 52.74 |
| Average Volume (20 Days) | 61,694 |
Short Selling Information
The latest short interest is 8,276, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 8,276 |
| Short Previous Month | 11,206 |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
In the last 12 months, InterCure had revenue of $84.76 million and -$11.20 million in losses. Loss per share was -$1.04.
| Revenue | 84.76M |
| Gross Profit | 12.77M |
| Operating Income | -21.09M |
| Pretax Income | -13.83M |
| Net Income | -11.20M |
| EBITDA | -17.36M |
| EBIT | -21.09M |
| Loss Per Share | -$1.04 |
Balance Sheet
The company has $14.64 million in cash and $57.41 million in debt, with a net cash position of -$42.77 million or -$3.91 per share.
| Cash & Cash Equivalents | 14.64M |
| Total Debt | 57.41M |
| Net Cash | -42.77M |
| Net Cash Per Share | -$3.91 |
| Equity (Book Value) | 124.33M |
| Book Value Per Share | 11.37 |
| Working Capital | 32.11M |
Cash Flow
In the last 12 months, operating cash flow was $5.55 million and capital expenditures -$1.17 million, giving a free cash flow of $4.38 million.
| Operating Cash Flow | 5.55M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 3.92M |
| Net Borrowing | -9.59M |
| Free Cash Flow | 4.38M |
| FCF Per Share | $0.40 |
Margins
Gross margin is 15.06%, with operating and profit margins of -24.89% and -13.22%.
| Gross Margin | 15.06% |
| Operating Margin | -24.89% |
| Pretax Margin | -16.32% |
| Profit Margin | -13.22% |
| EBITDA Margin | -20.48% |
| EBIT Margin | -24.89% |
| FCF Margin | 4.92% |
Dividends & Yields
InterCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.17% |
| Shareholder Yield | n/a |
| Earnings Yield | -17.59% |
| FCF Yield | 6.88% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 24, 2026. It was a reverse split with a ratio of 1:5.
| Last Split Date | Aug 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
InterCure has an Altman Z-Score of 0.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.15 |
| Piotroski F-Score | 4 |